Format

Send to

Choose Destination
Medicine (Baltimore). 2019 Dec;98(49):e18199. doi: 10.1097/MD.0000000000018199.

Management of delayed encephalopathy after CO poisoning: An evidence-based narrative review.

Author information

1
Department of Neurology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.

Abstract

BACKGROUND:

Approximately 10% to 30% patients develop delayed encephalopathy after acute CO poisoning (DEACMP). No specific treatment is available and poor prognosis is a characteristic of this disease. We aimed to evaluate the efficacy and safety of all therapies that have been tried in randomized controlled trial (RCT) for DEACMP.

METHODS:

We conducted a systematic search of the Cochrane, Embase, PubMed, and Web of Science databases.

RESULTS:

Overall, 4 RCTs were identified in our study. Both hyperbaric oxygen (HBO) and mesenchymal stem cell (MSC) transplantation were effective in DEACMP, and MSC seemed to be superior to HBO. The addition of dexamethasone, N-butylphthalide, or XingZhi-YiNao granules into HBO, or butylphthalide into MSC could achieve better neurological recovery in DEACMP patients but did not significantly increase the incidence of adverse events.

CONCLUSION:

Several therapies have shown positive results in treating DEACMP and need to be proven by further studies.

PMID:
31804341
PMCID:
PMC6919536
DOI:
10.1097/MD.0000000000018199
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center